Reocclusion: The flip side of coronary thrombolysis

Journal of the American College of Cardiology

Volumn 27, Issue 4, 1996, Pages 766-773

  Verheugt, Freek W A ^a   Meijer, Albert ^b   Lagrand, Wim K ^c   Van Eenige, Machiel J ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; STREPTOKINASE;

BLOOD CLOT LYSIS; HEART INFARCTION; HUMAN; INTRACARDIAC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION; REVIEW;

EID: 0029866994     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00492-0     Document Type: Review

References (62)

1. Schaer DH, Ross AM, Wasserman AG. Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. Circulation 1987;76 Suppl II:II-57-62.
2. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76: 142-54.
3. Simoons ML, Serruys PW, Van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717-28.
4. Simoons ML, Arnold AER, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-202.
5. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;19: 1-10.
6. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;22:1615-22.
7. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
8. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
9. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992;85:1706-12.
10. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79: 980-9.
11. Gash AK, Spann JF, Sherry S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986; 57:175-7.
12. Inoue K, Ochiai H, Kuwaki K. The mechanism of reocclusion after successful coronary thrombolysis as validated by percutaneous angioscopy [abstract]. J Am Coll Cardiol 1994;23:13A.
13. Veen G, Meijer A, Werter CJPJ, De Swart H, Verheugt FWA. Dynamic changes of culprit lesion morphology and severity after successful thrombolysis for acute myocardial infarction: an angiographic follow-up study [abstract]. J Am Coll Cardiol 1994;23:147A.
14. O'Brien JR. Shear-induced platelet aggregation. Lancet 1990;335:711-3.
15. Serruys PW, Simoons ML, Suryapranata H, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986;7:729-42.
16. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-91.
17. Takens BH, Brügemann J, Meer J van der, Heijer P den, Lie KI. Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex. Am J Cardiol 1990;65:1422-4.
18. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, Van der Pol JMJ, Van Eenige MJ. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT study. Circulation 1993;87:1524-30.
19. Medina A, Morales E, Hernandez E, et al. Angiographic evolution of coronary stenosis after thrombolytic therapy [abstract]. Eur Heart J 1993;14 Suppl:355.
20. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between four weeks and one year: effects of antiplatelet therapy. J Am Coll Cardiol 1995;25:218-23.
21. Timmis GC, Mammen EF, Ramos RG, et al. Hemorrhage vs. rethrombosis after thrombolysis for acute myocardial infarction. Arch Intern Med 1986; 146:667-72.
22. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
23. Uebis R, Dorr R, Reynen K, Effert S. Reokklusion nach erfolgreicher thrombolytischer Therapie beim akuten Myokardinfarkt. Klin Wochenschr 1988;66 Suppl XII:115-8.
24. Anderson JL, Rothbard RL, Hackworthy RA, et al. Trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988;11:1153-63.
25. Anderson JL, Sorensen SG, Moreno FL, et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation 1991;83:126-40.
26. Abbottsmith CW, Topol EJ, George BS, et al. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol 1990; 16:770-8.
27. Wall TC, Califf RM, George BS, et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis. J Am Coll Cardiol 1992;19:482-9.
28. Relik-van Wely L, Visser RF, Van der Pol JMJ, et al. Angiographically assessed coronary arterial patency in patients with acute myocardial infarction treated with anistreplase: results of the anistreplase reocclusion multi-center study (ARMS). Am J Cardiol 1991;68:296-300.
29. Neuhaus KL, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rtPA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19:885-91.
30. PRIMI Trial Study Group. Randomised double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-8.
31. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.
32. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue plasminogen activator and aspirin in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
33. Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995;25:582-9.
34. Brodie BR, Grines CL, Ivanhoe R, et al. Six months clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the primary angioplasty registry. Circulation 1994;90:156-62.
35. Zijlstra F, De Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
36. Krucoff MW, Croll MA, Pope JE, et al. Continuous 12-lead ST-segment recovery analysis in the TAMI7 study: performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993; 88:437-46.
37. Kwon K, Freedman SB, Wilcox I, et al. The unstable ST segment early after thrombolysis and its usefulness as a marker of recurrent coronary occlusion. Am J Cardiol 1991;67:109-15.
38. Rivers JT, White HD, Cross DB, Williams BF, Norris RM. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol 1990;16:340-8.
39. Ellis SG, Topol EJ, George BS, et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989;90:1159-65.
40. Veen G, Meijer A, Verheugt FWA, et al. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. J Am Coll Cardiol 1993;22: 1755-62.
41. Reiner JS, Lundergan CF, Van den Brand M, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. J Am Coll Cardiol 1994;24:1439-44.
42. Meijer A, Verheugt FWA, Van Eenige MJ, Werter CJPJ. Left ventricular function at 3 months after successful thrombolysis: impact of reocclusion without reinfarction on ejection fraction, regional function and remodeling. Circulation 1994;90:1706-14.
43. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
44. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet 1986;1:397-401.
45. Bang NU, Wilhelm OG, Clayman MD. After coronary thrombolysis and reperfusion, what next? J Am Coll Cardiol 1989;14:837-49.
46. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91:476-85.
47. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
48. Ohman EM, George BS, White CJ, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. Circulation 1994;90:792-9.
49. de Bono D, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-8.
50. Bleich SD, Nichols T, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66:1412-7.
51. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534-42.
52. GUSTO-IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90: 1631-7.
53. Antman ER. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
54. Lidon RM, Théroux P, Lespérance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-72.
55. Neuhaus KL, Von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994;90:1638-42.
56. Verheugt FWA, Van der Laarse A, Funke Küpper AJ, Sterkman LGW, Galema TW, Roos JP. Effects on infarct size, reinfarction and mortality of early intervention with low-dose (100 mg) aspirin in anterior wall acute myocardial infarction. Am J Cardiol 1990;66:267-70.
57. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19:671-7.
58. Sabia PJ, Powers ER, Ragosta M, Sarenbock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992;327:1825-31.
59. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993;87:1-20.
60. Beller GA. Role of myocardial perfusion imaging in evaluating thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1987;9:661-8.
61. Pierard L, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990;15: 1021-31.
62. Smart SC, Sawasa S, Ryan T, et al. Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Circulation 1993;88:405-15.